Dr. David Akintola, MD, PhD
Clinical Peptide Pharmacology Lead
Clinical Peptide Pharmacology Lead
Dr. David Akintola completed his MD at the University of Ibadan and his PhD in Clinical Pharmacology at the University of Oxford. His research focuses on pharmacokinetic optimization of peptide therapeutics, with particular expertise in sustained-release formulations. He has led Phase I-III clinical trials for 4 peptide drug candidates and serves on the editorial board of Peptide Science.
MD, University of Ibadan; PhD Clinical Pharmacology, University of Oxford
Peptide PK/PD, sustained-release formulations, clinical trial design
Sustained-release GLP-1 platform, Peptide PK modeling, Transdermal peptide delivery
An evidence-based exploration of Oneskin Peptide and its applications. Analysis of clinical data, mechanisms, and expert...
An evidence-based exploration of Atrial Natriuretic Peptide Anp Promotes and its applications. Analysis of clinical data...
An evidence-based exploration of Does Peptides Work and its applications. Analysis of clinical data, mechanisms, and exp...
An evidence-based exploration of Steroids Vs Peptides and its applications. Analysis of clinical data, mechanisms, and e...
An evidence-based exploration of Igf-1 Lr3 Peptide and its applications. Analysis of clinical data, mechanisms, and expe...
An evidence-based exploration of Peptides Regulation News Today and its applications. Analysis of clinical data, mechani...
PeptaVolt
License: BUS-2018-09134-MA
GMP: GMP-2023-6103-US
ISO: ISO 9001:2015 / ISO 13485:2016